Emergent Biosolutions, Inc. & Bavarian Nordic.- Notable Market Players in Biodefense Market
Biodefense is referred to the measures taken to restore biosecurity of a group of organism that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.
Market leaders operating in the market have undertaken various organic growth strategies in the biodefense market. The biodefense market majorly consists of the players such as Bavarian Nordic, Alnylam Pharmaceuticals, Inc., SIGA Technologies, Emergent BioSolutions Inc., Cleveland Bio Labs, Dynavax Technologies, Elusys Therapeutics, Inc., Soligenix, Altimmune, and Pluristem Therapeutics among others. Several organic approaches, such as product launches, and expansion/relocation in the biodefense market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Below is the list of the growth strategies done by the players operating in the biodefense market:
|
Year |
News |
|
March-2020 |
Alnylam Pharmaceuticals and Vir Biotechnology have expanded their partnership collaboration to include RNAi therapeutics, which is likely to treat SARS-CoV-2 infection, the coronavirus causing the current outbreak, COVID-19. |
|
June-2019 |
SIGA announced collaboration with Turnstone Biologics to provide TPOXX (tecovirimat) in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform. The collaboration will provide Turnstone with access to SIGA’s TPOXX oral antiviral capsules for use if required in future clinical programs. |
|
December-2016 |
Emergent BioSolutions Inc. received the Health Canada Approval for the company’s New Drug Submission (NDS) for its botulism antitoxin, BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. |
|
April-2018 |
Pluristem Therapeutics Inc. received FDA approval for the company’s Investigational New Drug (IND) application for its PLX-R18 cell therapy in the treatment of acute radiation syndrome (ARS). |
